Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Richman

Showing results (21-30 of 210) with videos related to

Pageof 21
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1985
Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravisC M Gomez, D P Richman
Biochimica Et Biophysica Acta|December 9, 2014
Myasthenia gravis and related disorders: Pathology and molecular pathogenesisJames C Ha, David P Richman
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1979
Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytesD P Richman, B G Arnason
Neurologic Clinics|May 1, 1994
Acquired myasthenia gravis. ImmunopathologyD P Richman, M A Agius
Seminars in Neurology|June 1, 1994
Myasthenia gravis: pathogenesis and treatmentD P Richman, M A Agius
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibodyM A Agius, D P Richman
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1983
Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myastheniaC M Gomez, D P Richman
Oncoimmunology|August 7, 2014
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinkingLee P Richman, Robert H Vonderheide
Frontiers in Immunology|May 28, 2020
Muscle-Specific Kinase Myasthenia GravisLucia S Borges, David P Richman
The Medical Clinics of North America|January 1, 1986
Systemic therapy of malignant melanomaJ Seeger, S P Richman, J C Allegra
Pageof 21

Showing results (21-30 of 210) with videos related to

Sort By:
Pageof 21
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1985
Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravisC M Gomez, D P Richman
Biochimica Et Biophysica Acta|December 9, 2014
Myasthenia gravis and related disorders: Pathology and molecular pathogenesisJames C Ha, David P Richman
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1979
Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytesD P Richman, B G Arnason
Neurologic Clinics|May 1, 1994
Acquired myasthenia gravis. ImmunopathologyD P Richman, M A Agius
Seminars in Neurology|June 1, 1994
Myasthenia gravis: pathogenesis and treatmentD P Richman, M A Agius
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibodyM A Agius, D P Richman
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1983
Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myastheniaC M Gomez, D P Richman
Oncoimmunology|August 7, 2014
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinkingLee P Richman, Robert H Vonderheide
Frontiers in Immunology|May 28, 2020
Muscle-Specific Kinase Myasthenia GravisLucia S Borges, David P Richman
The Medical Clinics of North America|January 1, 1986
Systemic therapy of malignant melanomaJ Seeger, S P Richman, J C Allegra
Pageof 21